
|Articles|August 11, 2016
FDA Grants Nivolumab Priority Review in Head and Neck Cancer
Author(s)Bobby Lazzara, MD
In this Medical News Minute, developed exclusively for Cancer Network, Dr. Bobby Lazzara discusses the recent priority review of nivolumab for use in metastatic head and neck cancer.
Advertisement
In this Medical News Minute, developed exclusively for Cancer Network, Dr. Bobby Lazzara discusses the recent priority review of nivolumab for use in recurrent or metastatic head and neck cancer, based on results of the CheckMate-141 study.
The study found that nivolumab improved overall survival (7.5 vs 5.1 months) over investigator’s choice.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on CancerNetwork
1
Frontline Sunvozertinib Improves PFS vs Chemotherapy in EGFR+ NSCLC
2
FDA Clears Investigator-Initiated IND for SRN-101 in Recurrent High-Grade Glioma
3
The Evolution of Artificial Intelligence in Oncology: Impact on Trials, Workflows, and Outcomes
4
Selinexor Combo Improves Spleen Volume Reduction in Myelofibrosis
5























































